Free Trial

Clorox (NYSE:CLX) Receives Hold (C-) Rating from Weiss Ratings

Clorox logo with Consumer Staples background

Key Points

  • Weiss Ratings has restated Clorox's stock rating to "hold (C-)," indicating a cautious outlook for the company's performance.
  • Multiple research firms have adjusted Clorox's price targets, with Jefferies Financial Group lowering it from $167.00 to $145.00.
  • Clorox's stock dropped by 2.1% to $117.85, with a recent trading volume significantly below its average.
  • Five stocks to consider instead of Clorox.

Clorox (NYSE:CLX - Get Free Report)'s stock had its "hold (c-)" rating restated by stock analysts at Weiss Ratings in a research note issued to investors on Tuesday,Weiss Ratings reports.

Several other research firms have also recently commented on CLX. Jefferies Financial Group cut their price target on Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Deutsche Bank Aktiengesellschaft cut their price target on Clorox from $135.00 to $128.00 and set a "hold" rating for the company in a research note on Monday. Barclays cut their price target on Clorox from $118.00 to $112.00 and set an "underweight" rating for the company in a research note on Tuesday, September 30th. UBS Group cut their price objective on Clorox from $134.00 to $128.00 and set a "neutral" rating for the company in a research report on Wednesday, October 8th. Finally, Morgan Stanley cut their price objective on Clorox from $150.00 to $137.00 and set an "equal weight" rating for the company in a research report on Friday, August 1st. One equities research analyst has rated the stock with a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the company's stock. According to data from MarketBeat.com, Clorox presently has a consensus rating of "Reduce" and an average price target of $131.64.

Read Our Latest Analysis on CLX

Clorox Stock Down 2.1%

CLX traded down $2.53 on Tuesday, reaching $117.85. The company's stock had a trading volume of 583,751 shares, compared to its average volume of 1,678,093. The stock has a 50 day moving average of $122.14 and a two-hundred day moving average of $128.40. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15. The company has a market capitalization of $14.35 billion, a price-to-earnings ratio of 18.07, a P/E/G ratio of 0.98 and a beta of 0.52. Clorox has a fifty-two week low of $116.53 and a fifty-two week high of $171.37.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.63. The business had revenue of $1.99 billion during the quarter, compared to the consensus estimate of $1.94 billion. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The company's revenue was up 4.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, analysts forecast that Clorox will post 7.15 EPS for the current fiscal year.

Insider Transactions at Clorox

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the firm's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $123.78, for a total value of $1,861,774.98. Following the sale, the chief operating officer directly owned 54,221 shares of the company's stock, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.63% of the company's stock.

Hedge Funds Weigh In On Clorox

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Clorox by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 15,845,496 shares of the company's stock valued at $1,902,569,000 after buying an additional 272,420 shares during the period. Invesco Ltd. boosted its position in Clorox by 138.3% during the 2nd quarter. Invesco Ltd. now owns 3,245,175 shares of the company's stock valued at $389,648,000 after purchasing an additional 1,883,465 shares during the period. Norges Bank acquired a new position in Clorox during the 2nd quarter valued at approximately $190,429,000. Northern Trust Corp boosted its position in Clorox by 2.3% during the 1st quarter. Northern Trust Corp now owns 1,528,920 shares of the company's stock valued at $225,133,000 after purchasing an additional 34,655 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its position in Clorox by 218.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,249,127 shares of the company's stock valued at $149,983,000 after purchasing an additional 856,873 shares during the period. 78.53% of the stock is currently owned by hedge funds and other institutional investors.

About Clorox

(Get Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Read More

Analyst Recommendations for Clorox (NYSE:CLX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Clorox Right Now?

Before you consider Clorox, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.

While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.